MALATHION - search results

Liên Minh Châu Âu - Tiếng Lít-va - EMA (European Medicines Agency)

ayvakyt

blueprint medicines (netherlands) b.v. - avapritinib - virškinimo trakto stromos navikai - kiti antinavikiniai vaistai agentai, baltymų kinazės inhibitoriai - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.

Liên Minh Châu Âu - Tiếng Lít-va - EMA (European Medicines Agency)

kaftrio

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cistinė fibrozė - kiti kvėpavimo sistemos produktai - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Liên Minh Châu Âu - Tiếng Lít-va - EMA (European Medicines Agency)

enhertu

daiichi sankyo europe gmbh - trastuzumab deruxtecan - krūties navikai - antinavikiniai vaistai - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Liên Minh Châu Âu - Tiếng Lít-va - EMA (European Medicines Agency)

skysona

bluebird bio (netherlands) b.v. - elivaldogene autotemcel - adrenoleukodystrophy - kiti nervų sistemos vaistai - treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age, with an abcd1 genetic mutation, and for whom a human leukocyte antigen (hla) matched sibling haematopoietic stem cell donor is not available.

Liên Minh Châu Âu - Tiếng Lít-va - EMA (European Medicines Agency)

lumykras

amgen europe bv - sotorasib - karcinoma, nesmulkiųjų ląstelių skausmas - antinavikiniai vaistai - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.